Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)

NCT06349473 is registered in ClinicalTrials.gov with Equilibra Bioscience LLC as lead sponsor.

NCT NCT06349473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06349473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)
Lead sponsor
Equilibra Bioscience LLC
Phase
Phase 1
Overall status
Recruiting
Start date
May 10, 2024
Completion date
September 28, 2026
Enrollment
31 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

factor vii deficiency, healthy participants, hemophilia a, hemophilia b